Which medication is better, empagliflozin or dapagliflozin, for patients with chronic kidney disease?

No direct comparative evidence between empagliflozin and dapagliflozin for patients with chronic kidney disease was identified. Indirect evidence suggests both have renal protective effects, with some studies favoring empagliflozin in slowing CKD progression.

Authors

Tripdatabase

Publication Details

Journal: Zenodo (CERN European Organization for Nuclear Research)
Published: 2026-11-04
DOI: https://doi.org/10.5281/zenodo.23954906
Primary Topic: Diabetes Treatment and Management
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Which medication is better, empagliflozin or dapagliflozin, for patients with chronic kidney disease?

Tripdatabase

Nov 4, 2026

Zenodo (CERN European Organization for Nuclear Research)

Diabetes Treatment and Management

article

Which medication is better, empagliflozin or dapagliflozin, for patients with chronic kidney disease?

Tripdatabase

November 4, 2026article en

Abstract

Zenodo (CERN European Organization for Nuclear Research)

Openalex Percentile: Top 12%

Diabetes Treatment and Management

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon

Which medication is better, empagliflozin or dapagliflozin, for patients with chronic kidney disease? — Tripdatabase · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS